

Stock Code : 4108



懷特生技新藥(股)公司
PhytoHealth Corporation

Handbook for the 2026 Annual Meeting of Shareholders

Form of meeting: Physical Meeting

Meeting Time: June 9, 2026

Meeting Place: 3rd Fl., No.10 Shih-er Rd., Yangmei District, Taoyuan City

Table of Contents

I. Meeting Procedures	1
II. Meeting Agenda	2
1. Report Items.....	3
2. Acknowledged Matters	4
3. Election Matters	6
4. Other Matters	7
5. Extemporaneous Motions	8
III. Attachments	
1. The 2025 Business Report	9
2. The 2025 Audit Committee’s Review Report	15
3. Status Report on the Execution of Plans to Enhance Operations for 2012 and 2020 Capital Increase Through Cash Injection.....	16
4. Comparison Table of Sustainable Development Best Practice Principles.....	20
5. 2025 Independent Auditors’ Report and Financial Statements	23
6. Director and Independent Director Candidates.....	41
7. Details on Directors and Their Representatives Holding Concurrent Positions in Other Companies.....	48
IV. Appendices	
1. Rules of Procedure for Shareholder Meeting.....	49
2. Articles of Incorporation.....	57
3. Rules for Director Elections.....	63
4. Shareholding of Directors	66

I. Meeting Procedures

PhytoHealth Corporation

Procedure for the 2026 Annual Meeting of Shareholders

1. Calling the Meeting to Order (Report the total number of shares present)
2. Chairperson Remarks
3. Report Items
4. Acknowledged Matters
5. Election Matters
6. Other Matters
7. Extemporaneous Motions
8. Adjournment

II. Meeting Agenda

PhytoHealth Corporation

Procedure for the 2026 Annual Meeting Agendas

Form of Meeting: Physical Meeting

Meeting Time: 9:00a.m., Tuesday, June 9, 2026

Meeting Place: 3rd Fl., No.10 Shih-er Rd., Yangmei District, Taoyuan City

1. Call the Meeting to Order (Report the total number of shares present)
2. Chairperson Remarks
3. Report Items
 - (1) The 2025 Business Report.
 - (2) The 2025 Audit Committee's Review Report.
 - (3) Status Report on the Execution of Plans to Enhance Operations for 2012 and 2020 Capital Increase Through Cash Injection.
 - (4) Report on amendment to "Sustainable Development Best Practice Principles" .
4. Acknowledged Matters
 - (1) Adoption of 2025 the Financial Statements and Business Report.
 - (2) Adoption of the Proposal for 2025 Deficit Compensation.
5. Election Matters

Elections of Board Directors.
6. Other Matters

Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business.
7. Extemporaneous Motions
8. Adjournment

1. Report Items

(1) The 2025 Business Report.

Explanation : Please refer to Attachment 1 (page 9~14) for detailed Business Reports.

(2) The 2025 Audit Committee's Review Report.

Explanation : Please refer to Attachment 2 (page 15) for 2025 Audit Committee's Review Report.

(3) Status Report on the Execution of Plans to Enhance Operations for 2012 and 2020 Capital Increase through Cash Injection .

Explanation : Please refer to Attachment 3 (page 16~19) for Status Report on the Execution of Plans to Enhance Operations for 2012 and 2020 Capital Increase Through Cash Injection Report.

(4) Report on the Revision of the " Sustainable Development Best Practice Principles " .

Explanation : (i).In response to regulatory amendments and practical needs, provisions relating to the new Corporate Governance Blueprint, the enhancement of biodiversity and ecosystem conservation, sustainable resource use, and fair and equitable benefit-sharing were revised and supplemented. The proposed amendments to certain provisions of the Company' s "Sustainable Development Best Practice Principles"were approved by the Board of Directors on February 25, 2026.

(ii). Please refer to Attachment 4 (page 20~22) for Amendment comparison table of " Sustainable Development Best Practice Principles " .

(iii).Report.

2. Acknowledged Matters

Subject : 1. Adoption of 2025 the Financial Statements and Business Report.
(Proposed by the Board of Directors)

Explanation : (i).The company's 2025 financial statements and business report were approved by the Audit Committee and the resolution of the Board of Directors on February 25, 2026. The financial statements have been audited by Ernst & Young Accountants Wang, Yahn-Jyun and Yu Chien-Ju, and issued "Unqualified Opinion".

(ii). Please refer to Attachment 1 (page 9~14) for detailed Business Reports and Attachment 5 (page 23~40) for Financial Statements.

(iii). Please acknowledge.

Resolution :

Subject : 2. Adoption of the Proposal for 2025 Deficit Compensation.
(Proposed by the Board of Directors)

Explanation : (i). The Company's beginning accumulated deficit amounted to NT\$264,606,693.

After adding NT\$40,747,285 from the Disposal of investments in financial assets at fair value through, and deducting the net loss after tax of NT\$58,200,432 for 2025, the ending accumulated deficit amounted to NT\$282,059,840.

(ii). This proposal was approved by the Audit Committee and the Board of Directors on February 25, 2026.

(iii). Please refer to 2025 Deficit Compensation as follows :

Unit: NT\$

Item	Amount
Losses to be made up at the beginning of the period	(264,606,693)
Plus:Disposal of investments in equity instruments measured at FVOCI	40,747,285
Less:Net loss after tax in 2025	(58,200,432)
Losses to be made up at the end of the period	(282,059,840)

Chairman : Lee Yi-Li

Manager : Lee I-Lin

Accounting supervisor : Huang Chih-Yuan

(iv). Please acknowledge.

Resolution :

3. Election Matters

Subject : Elections of Board Directors (Proposed by the Board of Directors)

Explanation : (i).The company currently has eleven directors (including three independent directors),

 Their term of office will expire on May 23, 2026. Pursuant to the Company Act, they may continue to perform their duties until the newly elected directors elected at the 2026 Annual Shareholders' Meeting take office.

(ii).According to Article 17 of the Company's Articles of association, thirteen directors (including four independent directors) were elected at this Annual Shareholders' Meeting. Shareholders elect the new directors from the list of candidates. The newly appointed director shall take office from the date of appointment and serve a term of three years from June 9, 2026 to June 8, 2029.

(iii).The nomination of candidates for directors and independent directors was approved by the Board of Directors on February 25, 2026. For the list of candidates and the relevant information thereof, Please refer to Attachment 6 (page 41~47) for Elections of Board Directors.

(iv).Please refer to Appendix 3 (page 63~65) for "Rules for Director Elections".

(v).Please conduct the election.

Election results :

4. Other Matters

Subject : Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business.(Proposed by the Board of Directors)

Explanation : (i).Pursuant to Article 209 of the Company Law, directors should explain the important content of their actions to the shareholders' meeting and obtain their approval for actions that fall within the scope of the company's business for themselves or others.

(ii).Please refer to Attachment 7 (page 48) for Directors and their representatives concurrently hold positions in other companies.

(iii).This case has been approved by the board of directors on February 25, 2026. °

(iv).Please discuss.

Resolution :

5. Extemporaneous Motions

6. Adjournment

III. Attachments

Attachment 1

PhytoHealth Corporation The 2025 Business Report

I. 2026 Management Policy

PhytoHealth Corporation has long been dedicated to the research and development of Astragalus-based botanical drugs. Leveraging its solid development expertise, the Company continues to expand the commercial potential and clinical application value of its products.

PG2 Lyo. Injection 500mg (PG2®), the Company's prescription drug, is the world's only approved prescription medication indicated for the treatment of moderate-to-severe Cancer Related Fatigue (CRF). On March 1, 2021, it was also included in Taiwan's National Health Insurance reimbursement scheme, benefiting a broad population of breast cancer patients and at the same time driving steady growth in the self-pay market. At present, PG2 Lyo. Injection 500mg (PG2®), has been adopted by approximately 90% of domestic medical centers, and its clinical value has been widely recognized by the medical community. Following commercialization, the Company has continued to invest in clinical research. Its breast cancer-related study results have been presented at the American Society of Clinical Oncology (ASCO), while research on the use of PG2 Lyo. Injection 500mg (PG2®) in combination with preoperative chemoradiotherapy for esophageal cancer has also demonstrated a survival benefit and has been presented at the European Society for Medical Oncology (ESMO), highlighting the product's internationally recognized clinical evidence and academic visibility.

In addition, Oraphine® 60mg Soft Capsule is the world's only oral nalbuphine analgesic indicated for the treatment of moderate-to-severe acute pain. With the advantages of oral convenience and a lower risk of dependence, it has already been adopted by a number of medical centers. The Company is also actively engaged in discussions regarding distribution and technology licensing partnerships in Europe and Southeast Asia, targeting the substantial demand in the postoperative pain management market and positioning the product for promising future market development.

In response to the global aging trend and the continued rise in health and wellness awareness, Phytohealth Corporation has extended its focus from botanical drug development into the field of botanical health products. The Company has entered into discussions with leading domestic and international health product companies regarding collaboration on functional ingredients, and will continue to deepen its clinical development efforts and international partnership strategy, actively capturing opportunities in the global anti-aging and health and wellness markets and laying a solid foundation for the Company's long-term growth.

II. Implementation Overview and Results of the Business Plan for the Year 2025

1. PG2 Lyo. Injection 500mg (PG2®) Clinical Research:

- (1) The Company's refined manufacturing facility completed the GMP inspection for the active pharmaceutical ingredient in July 2025, and the certification may be extended through October 2028.
- (2) Continued accumulation of real-world clinical effectiveness data for NHI-reimbursed use: To comply with the National Health Insurance Administration's requirement to

submit post-reimbursement clinical effectiveness data, seven medical centers—Taipei Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, Tri-Service General Hospital, China Medical University Hospital, Taichung Veterans General Hospital, Kaohsiung Medical University Hospital, and E-Da Hospital—jointly conducted a real-world data (RWD) research project on reimbursed treatment for cancer-related fatigue. The study aimed to collect case data from 200 breast cancer patients receiving NHI-reimbursed PG2®. According to the benefit evaluation results, PG2® effectively improved fatigue and achieved high medication satisfaction among breast cancer patients treated for cancer-related fatigue under the NHI reimbursement scheme. The final benefit evaluation report was submitted to the NHIA on August 27, 2024. Study results were presented at the 2024 Taipei International Breast Cancer Symposium (TIBCS) on October 26, 2024, and at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 11, 2024. A manuscript is currently being prepared. Following approval at the joint reimbursement review meeting in December 2024, the product remained covered under NHI reimbursement, and the Company completed the reimbursement agreement signing with the NHIA on February 3, 2025.

- (3) Clinical trial on the impact of PG2® in breast cancer chemotherapy:
This study evaluated whether combining chemotherapy with PG2® in early-stage breast cancer patients could reduce chemotherapy-related side effects, improve treatment adherence, and potentially enhance therapeutic outcomes. The study results were presented at the 2023 ASCO Annual Meeting on June 4, 2023. The clinical study report has been completed, and the paper has been published in Scientific Reports of the Nature portfolio (IF = 3.8).
- (4) Clinical trial on the impact of PG2® in preoperative chemoradiotherapy for esophageal cancer: All patients in this study completed the trial, and the statistical analysis showed positive results. The findings were presented at the 2024 ESMO Congress on September 16, 2024. All patients have completed survival follow-up and the data have been locked. The final statistical analysis has been completed, and a close-out meeting with the principal investigators will be convened in January 2026 for discussion. A manuscript is currently being prepared for submission.
- (5) Pilot study of PG2® for chemotherapy-related fatigue in breast cancer: To support future international clinical trials and address overseas market conditions, the Company has launched a pilot study exploring different combination treatment strategies. Patient enrollment has begun at a leading medical center, with data cleaning and unblinding targeted for completion in the first quarter of 2026. The results will serve as a reference for planning subsequent international Phase III trial strategies.
- (6) Multiple basic research projects were conducted to explore new indications and clinical mechanisms of Astragalus polysaccharides:
 - A. Mechanistic study on the effects of Astragalus polysaccharides on gut microbiota and anticancer immune regulation. In recent years, research on the relationship between gut microbiota and immune regulation has grown rapidly, further confirming the importance of gut flora in immune function. Preliminary results have shown that Astragalus polysaccharides may regulate gut microbiota, inhibit harmful bacteria, and promote the growth of beneficial probiotic strains involved in immune modulation. Preliminary positive results were obtained in 2025, and the Company will subsequently complete related patent planning and publication.
 - B. Study on the effect of PhytoHealth Astragalus oral Astragalus polysaccharides in combination with targeted therapies on drug-resistant cancer cells. Preliminary results have shown that Astragalus polysaccharides, when combined with targeted therapies, could reduce resistance in lung cancer cell lines resistant to targeted drugs, thereby improving the cytotoxic effect of targeted therapies on cancer cells. The study has now been expanded to additional cancer types, relevant testing has

been completed, results reports have been obtained, and multinational patent applications have been initiated. A patent approval was obtained in Taiwan in March 2025.

- C. Development of multiple efficacy-based health ingredient materials based on Astragalus polysaccharides. During the year, multiple efficacy animal studies and in vitro validation of gastrointestinal microbiota regulation were completed. The Company will also plan multinational patent applications to facilitate future business matching and negotiations.

2. Oraphine[®] 60mg Soft Capsule

This product received marketing authorization from the TFDA in March 2020. To strengthen post-marketing clinical evidence in target markets and promote the collection of real-world clinical data, the Company has launched a multicenter post-marketing study on postoperative pain management following orthopedic surgery. During the year, patient enrollment continued, and subsequent publication plans are being arranged. In parallel, the Company is also conducting regulatory consultations and sales agency discussions for marketing authorization in countries across Europe, Asia, and other regions.

3. PHN031

The Phase IIa clinical trial approved by both the U.S. FDA and Taiwan TFDA has been completed. In accordance with Good Agricultural and Collection Practice (GCAP) for medicinal materials, a germplasm conservation and cultivation program has been carried out. The medicinal materials planted under the program were scheduled for harvest in February 2025. The Company continues to follow international Chemistry, Manufacturing and Controls (CMC) standards to ensure batch-to-batch consistency in production. It will collaborate with official agricultural improvement agencies with the goal of gradually expanding the production capacity of functional medicinal materials, and will evaluate their potential applications in the health supplement market. In 2026, the Company will continue product quality analysis and plan validation studies.

4. PHN033

The Phase IIa clinical trial approved by both the U.S. FDA and Taiwan TFDA has been completed. In accordance with Good Agricultural and Collection Practice (GCAP) for medicinal materials, a germplasm conservation and cultivation program has been carried out. The medicinal materials planted under the program were scheduled for harvest in February 2025. The Company continues to follow international Chemistry, Manufacturing and Controls (CMC) standards to ensure batch-to-batch consistency in production. It will collaborate with official agricultural improvement agencies with the goal of gradually expanding the production capacity of functional medicinal materials, and will evaluate their potential applications in the health supplement market. In 2026, the Company will continue product quality analysis and plan validation studies.

5. Astragalus Health Products and Raw Materials

Through its patented botanical drug production technology and use of premium membranous milkvetch (*Astragalus membranaceus*) raw materials, PhytoHealth has developed its proprietary extract, PhytoHealth Astragalus Polysaccharides, and launched Qi+ Liquid Herbal Energy and PhytoHealth Astragalus Capsule, health supplement products designed for sub-healthy populations to replenish vital energy. In addition, using refined Astragalus polysaccharides (rAPP) as the main ingredient, the Company developed PhytoHealth Astragalus, a pharmaceutical-grade health supplement intended for cancer

Project \ Year	2025
Operating revenue (A)	134,576 (in thousands)
Research and development expenses (B)	126,152 (in thousands)
Total number of employees (C)	120 people
Total R&D personnel (D)	32 people
R&D expenditure ratio B/A	94%
R&D manpower to total manpower D/C	26%

2. 2025 Annual Research and Development Results

Important Product Research and Development Achievements:

Product	Indications/R & D direction	R & D progress
PG2 Lyo. Injection 500mg(PG2®)	Moderate to severe cancer-related fatigue	• Collaborated with medical societies related to oncology care to hold an academic symposium on the pharmacological treatment of moderate to severe cancer-related fatigue in celebration of the 15th anniversary of PG2® commercialization, thereby strengthening continuing education on clinical assessment and pharmacological evidence for cancer-related fatigue across Taiwan. • Accelerated patient enrollment in the exploratory clinical trial of PG2® combined with breast cancer chemotherapy. • Completed analysis of the exploratory clinical trial of PG2® combined with preoperative chemoradiotherapy for esophageal cancer. • Conducted a real-world evidence (RWE) research project on PG2® combined with postoperative chemotherapy and targeted therapy for colorectal cancer. • Planned and implemented basic research projects to explore new indications and clinical mechanisms of Astragalus polysaccharides. • Evaluated regulatory requirements for botanical drugs in overseas markets and actively pursued licensing and co-development opportunities.
Oraphine® 60mg Soft Capsule (PHN131)	Acute moderate to severe pain	• Conducted regulatory consultations and bridging clinical trial assessments for marketing approval in Europe, the United States, and other Asian countries, while also discussing overseas licensing opportunities. • Carried out Taiwan market launch planning and collected clinical evidence to support domestic and international sales promotion.
PHN031	Osteoporosis	• Completed the germplasm conservation and cultivation program for medicinal plant materials. • Ensured batch stability and availability of medicinal material sources in accordance with international CMC standards. • In light of the target indication and market competitiveness, the Company has integrated its existing development achievements and

		product mechanisms of action to pursue the commercialization of a dual-function health supplement with stronger market potential for bone protection and body fat reduction.
PHN033	Diabetic nephropathy	• Completed the germplasm conservation and cultivation program for medicinal plant materials. • Ensured batch stability and availability of medicinal material sources in accordance with international CMC standards. • In light of the target indication and market competitiveness, the Company has integrated its existing development achievements and product mechanisms of action to pursue the commercialization of health supplement with stronger market potential.

Chairman : Lee Yi-Li

Manager : Lee I-Lin

Accounting Supervisor : Huang Chih-Yuan

Attachment 2

PhytoHealth Corporation Audit Committee's Review Report

We have agreed and submitted the Company's 2025 financial statements to the Board of Directors and obtained the approval of the Board of Directors. The financial statements have been audited by Ernst & Young Taiwan engaged by the Board of Directors with an unqualified opinion in the independent auditor's report.

We audited the Company's 2025 business report and deficit compensation proposal which have been resolved by the Board of Directors and has concluded that both of them are in accordance with the related regulations. Pursuant to the regulations set forth in Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, a report is submitted as above. Please review.

Sincerely,

PhytoHealth Corporation 2026 Annual General Meeting of Shareholders

Convener of Audit Committee : Lin Shoei-Loong

February 25, 2026

Attachment 3

PhytoHealth Corporation

Status Report on the Execution of Plans to Enhance Operations for 2012 and 2020 Capital Increase through Cash Injection

I. PHN012/PHN014/PHN015(PG2 Lyo. Injection 500mg):

1. Execution of Clinical Trials on "PG2 Lyo. Injection 500mg " for the Impact on Breast Cancer Chemotherapy:
The clinical trial has been completed. The study results were presented at the 2023 ASCO Annual Meeting (American Society of Clinical Oncology) on June 4, 2023. The clinical study report has been finalized, and the paper has been published in Scientific Reports, a Nature portfolio journal (IF = 3.8).
2. Execution of Clinical Trials on "PG2 Lyo. Injection 500mg " for the Impact on Preoperative Chemoradiotherapy in Esophageal Cancer:
All patients in this trial have completed the study and entered the follow-up period. Preliminary statistical analysis has been completed. The results were presented at ESMO 2024 (European Society for Medical Oncology Congress) on September 16, 2024. A close-out meeting with the principal investigator was held on January 15, 2026 for discussion, and preparation for academic manuscript submission is underway. In terms of patent strategy, a Japanese invention patent titled "Use of Astragalus Polysaccharide Extract in the Manufacture of a Medicament for Enhancing the Effect of Cancer Immunotherapy / METHOD FOR ENHANCING EFFECT OF IMMUNOTHERAPY FOR CANCER" was granted in August 2022. Patents have now been obtained in the United States, Taiwan, South Korea, and Japan.
3. Execution of a Real-World Evidence (RWE) Study on PG2® Combined with Postoperative Chemotherapy and Targeted Therapy in Colorectal Cancer:
This study is designed to retrospectively collect data from colorectal cancer patients at Taichung Veterans General Hospital and Chung Shan Medical University Hospital who have received postoperative chemotherapy and targeted therapy, in order to investigate the impact of PG2® on prognosis and survival in cancer treatment. To date, preliminary enrollment and analysis of 65 patients have been completed. Initial findings were presented at the 46th ESPEN Congress (European Society for Clinical Nutrition and Metabolism) on September 8, 2024, and at ASSMN 2024 (the 3rd Asian Surgical Metabolism and Nutrition Meeting and the Winter Meeting of the Taiwan Surgical Association of Gastroenterology) on October 26, 2024. Two international clinical trial plans are being developed, with the goal of expanding the international market and new indications for PG2®.
4. Planning Two International Clinical Trials to Expand the Global Market and New Indications for PG2 Lyo. Injection 500mg:
 - (1) Based on the conclusions of the clinical expert advisory meeting held on March 14, 2021, a pivotal multinational clinical trial of PG2® and pre-IND/pre-clinical-trial consultation with the U.S. FDA and Germany's BfArM (for Germany / EU member states) are being planned. The trial concept synopsis has already been completed. Based on the results of the pilot study at National Taiwan University Hospital, the feasibility of Germany and other EU countries participating in the multinational clinical trial will be evaluated.
 - (2) Pilot Study on Cancer-Related Fatigue (CRF) in Breast Cancer Chemotherapy
The design of the pivotal clinical trial planned for the United States and Europe has already been drafted. In response to overseas market conditions, dosing has been adjusted to weekly administration. To obtain preliminary validation data for estimating the final sample size, a four-week pilot study with the same design is being conducted first at National Taiwan University Hospital. The target population is breast cancer patients

evaluable cases were included in the analysis. Statistical analysis and the principal investigator close-out meeting have been completed, and the final benefit assessment report was submitted to the NHIA on August 27, 2024. The study results were submitted for presentation at the 2024 TIBCS (Taipei International Breast Cancer Symposium) and the 2024 SABCS (San Antonio Breast Cancer Symposium), and the manuscript is currently under peer review at an academic journal. The product again passed the joint reimbursement review meeting in December 2024 and continued to be included in NHI reimbursement. On February 3, 2025, the Company completed signing the reimbursement agreement with the NHIA.

II. PHN131(Oraphine® 60mg Soft Capsule):

Oraphine® 60mg Soft Capsule received TFDA approval on March 18, 2020 (License No. MOHW-Taiwan 060459). Efforts are currently underway to negotiate technology licensing and product distribution agreements with domestic and international companies. Additionally, regulatory consultations and bridging clinical trial evaluations are being conducted for market approvals in China, the US, and other Asian countries:

1. Real-world data collection and post-marketing clinical development: In line with domestic launch preparations and the target patient populations and indications for marketed use, the Company is promoting the collection of real-world clinical data, developing niche-market clinical applications, and preparing clinical reports for submission and publication to support promotion and application both domestically and internationally. A multicenter post-marketing study on postoperative pain management in orthopedic surgery is currently being planned and implemented. Enrollment was successively initiated at five medical centers in Taiwan in Q3 2024. As of Q4 2025, a cumulative total of 176 cases had been completed. Enrollment has been closed and the study has entered the statistical analysis stage.
2. Basic research and patent applications related to the Oraphine® formulation: Basic research related to the Oraphine® formulation was completed in Q4 2022. The related results were compiled, and a continuation patent application for a new invention related to Oraphine® was filed in June 2023. Corresponding patent applications have also been filed in the United States, Taiwan, multiple Southeast Asian countries (Malaysia, Thailand, Singapore, the Philippines, and Vietnam), Europe, and globally through the PCT route.
3. Preparation for scientific advice prior to registration in Germany / the EU: The Company is working with Company A in Germany, with which a Letter of Intent (LoI) has been signed, to prepare for scientific advice with Germany's BfArM / the EU EMA prior to registration. Since June 2025, both parties have successively reviewed and exchanged comments on the CTD dossier for Oraphine® registration, and the scientific advice application was completed and submitted in January 2026.

III. PHN031:

The Phase IIa clinical trials authorized by the U.S. FDA and Taiwan TFDA have been completed. A germplasm preservation and cultivation program is being carried out in accordance with Good Agricultural and Collection Practice (GCAP) for medicinal materials. The medicinal materials planted under the plan were scheduled for harvest in February 2025. The Company continues to follow international Chemistry, Manufacturing, and Controls (CMC) standards to ensure batch-to-batch consistency in production. In view of the target indications and market competitiveness, the Company is integrating existing development results and product mechanisms of action and is investing in the commercialization of a dual-function

health product with greater market potential for bone protection and body fat reduction.

IV. PHN033:

The Phase IIa clinical trials authorized by the U.S. FDA and Taiwan TFDA have been completed. A germplasm preservation and cultivation program is being carried out in accordance with Good Agricultural and Collection Practice (GCAP) for medicinal materials. The medicinal materials planted under the plan were scheduled for harvest in February 2025. The Company continues to follow international Chemistry, Manufacturing, and Controls (CMC) standards to ensure batch-to-batch consistency in production. In view of the target indications and market competitiveness, the Company is integrating existing development results and product mechanisms of action and is investing in the commercialization of functional health products with greater market potential.

Attachment 4

PhytoHealth Corporation

Comparison Table of Sustainable Development Best Practice Principles

After amendment	Before amendment	Reason for amendment
Article 3 : In promoting sustainable development initiatives, the company shall, in its corporate management guidelines and business operations, give due consideration to the rights and interests of stakeholders and, while pursuing sustainable operations and profits, also give due consideration to the environment, society and corporate governance. <u>The company shall, in accordance with the materiality principle, conduct risk assessments of environmental, social and corporate governance issues pertaining to company operations and establish the relevant risk management policy or strategy.</u>	Article 3 : In promoting sustainable development initiatives, the company shall, in its corporate management guidelines and business operations, give due consideration to the rights and interests of stakeholders and, while pursuing sustainable operations and profits, also give due consideration to the environment, society and corporate governance.	In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.
Article 15 : The company is advised to take into account the effect of business operations on ecological efficiency, promote and advocate the concept of sustainable consumption, and conduct research and development, procurement, production, operations, and services in accordance with the following principles to reduce the impact on the natural environment, <u>biodiversity</u>, and <u>human</u> beings from their business operations: (Omitted) 6.Improve efficiency of products and services. 7. <u>Enhance the conservation of marine and terrestrial biodiversity and ecosystems, promote the sustainable use of resources, and ensure fair and equitable benefits.</u>	Article 15 : The company is advised to take into account the effect of business operations on ecological efficiency, promote and advocate the concept of sustainable consumption, and conduct research and development, procurement, production, operations, and services in accordance with the following principles to reduce the impact on the natural environment and human beings from their business operations: (Omitted) 6.Improve efficiency of products and services.	With reference to initiatives such as the United Nations Convention on Biological Diversity, and in consideration of relevant laws and regulations on marine and nature conservation, amendments have been made to enhance the conservation of biodiversity and ecosystems, promote the sustainable use of resources, and ensure fair and reasonable benefits.

After amendment	Before amendment	Reason for amendment
Article 17 : The company is advised to assess the current and future potential risks and opportunities that climate change may present to enterprises and to <u>adopt related measures</u>. The company is advised to <u>adopt standards or guidelines generally used in Taiwan and abroad to enforce corporate greenhouse gas inventory and to make disclosures thereof, the scope of which shall include the following:</u> 1. <u>Direct greenhouse gas emissions: emissions from operations that are owned or controlled by the company.</u> 2. <u>Indirect greenhouse gas emissions: emissions resulting from the utilization of energy such as imported electricity, heating, or steam.</u> 3. <u>Other indirect emissions: emissions resulting from corporate activities that are not indirect emissions from energy, but are from other sources of emissions owned or controlled by the company.</u> <u>The company is advised to compile statistics on greenhouse gas emissions, volume of water consumption and total weight of waste and to establish policies for energy conservation, carbon and greenhouse gas reduction, reduction of water consumption or management of other wastes. The company' carbon reduction strategies should include obtaining carbon credits and be promoted accordingly to minimize the impact of their business operations on climate change.</u>	Article 17 : The company is advised to assess the current and future potential risks and opportunities that climate change may pose to its current and future operations, and compile statistics on greenhouse gas emissions, water consumption, and the total weight of waste. The company should also establish policies on energy conservation and carbon reduction, greenhouse gas reduction, water conservation, and other waste management measures in order to reduce the impact of its operational activities on climate change.	In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.
Article 21 : The company is advised to create an environment conducive to the development of their employees' careers and establish effective training programs to foster career skills. <u>It is advisable for the company to establish placement programs to</u>	Article 21 : The company is advised to create an environment conducive to the development of their employees' careers and establish effective training programs to foster career skills.	To promote industry–academia integration and support students' career development, the company should

After amendment	Before amendment	Reason for amendment
<u>cultivate future industry talents.</u> <u>The company shall establish and implement reasonable employee welfare measures (including remuneration, leave and other welfare etc.) and appropriately reflect the business performance or achievements in the employee remuneration, to ensure the recruitment, retention, and motivation of human resources, and achieve the objective of sustainable operations.</u>	The company shall appropriately reflect its <u>business</u> performance or achievements in its employee compensation policies to ensure the recruitment, retention, and motivation of human resources, thereby achieving the goal of sustainable operations.	establish industry-academia collaboration programs to cultivate future talent for the industry.
<u>Article 27-1 :</u> <u>The company is advised to dedicate resources to cultural and art activities or the cultural and creative industry constantly through endowments, sponsorships, investments, procurements, strategic cooperation, volunteering technical services of enterprises, or other forms of support, to promote cultural development.</u>	(New)	In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.
Article 31 : The Company's Sustainable Development Best Practice Principles shall be implemented after approval by the Board of Directors and shall be reported to the shareholders' meeting. The same procedure shall apply to any amendments. The principles were first established under the title "Corporate Social Responsibility Best Practice Principles" on April 29, 2014. The 1st revision was made on February 25, 2015. The 2nd amendment, which also changed the name to "Sustainable Development Best Practice Principles," was made on February 23, 2022. <u>The 3rd amendment was made on February 25, 2026.</u>	Article 31 : The Company's Sustainable Development Best Practice Principles shall be implemented after approval by the Board of Directors and shall be reported to the shareholders' meeting. The same procedure shall apply to any amendments. The principles were first established under the title "Corporate Social Responsibility Best Practice Principles" on April 29, 2014. The 1st revision was made on February 25, 2015. The 2nd amendment, which also changed the name to "Sustainable Development Best Practice Principles," was made on February 23, 2022.	Addition of Amendment Frequency and Date.

English Translations of Consolidated Financial Statements Originally Issued in Chinese
PHYTOHEALTH CORPORATION AND ITS SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)

ASSETS	Notes	As of	
		December 31, 2025	December 31, 2024
Current assets			
Cash and cash equivalents	4, 6	\$86,795	\$22,723
Financial assets at fair value through profit and loss, current	4, 6	2,500	12,000
Financial assets at amortized cost, current	4, 6, 8	981,430	1,045,490
Accounts receivable, net	4, 6	9,345	20,841
Accounts receivable-related parties, net	4, 6, 7	26,991	19,728
Current tax assets	4	27	10
Inventories	4, 6	126,082	155,892
Prepayments	6	30,684	29,331
Other current assets		68	378
Total current assets		1,263,922	1,306,393
Non-current assets			
Financial assets at fair value through other comprehensive income, non-current	4, 6	837,772	848,998
Financial assets measured at amortized cost, non-current	4, 6	792	887
Property, plant and equipment	4, 6, 7	170,579	196,941
Right-of-use assets	4, 6, 7	13,873	16,142
Intangible assets	4, 6	60,005	66,481
Prepayments for equipment		2,880	444
Refundable deposits	7, 8	3,254	3,384
Total non-current assets		1,089,155	1,133,277
Total assets		\$2,353,077	\$2,439,670

(The accompanying notes are an integral part of the consolidated financial statements.)

Attachment 6

PhytoHealth Corporation

Director and Independent Director Candidates

NO.	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. of shares currently held (Shares)	Remarks
1	Director	Maywufa Company Ltd. Representative:LeeYi-Li	female	Owner/President Management,Harvard School. MBA,Rutgers University. BBA in Finance, National Taiwan University.	Supervisor ,Taiwan Bio Industry Organization. Fierce Women in Biopharma, Taiwan 2016 . Vice President, International Global Corporate, Standard Chartered Bank Vice President,Credit Agricole Corporate and Investment Bank Manager,Corporate Banking Group Citibank,N.A.	Chairman,PhytoHealth Corp. Chairman/General Manager,Amcad BioMed Corp. Vice Chairman,Maywufa Company Ltd. Chairman,Broadsound Corporation Director,Maywufa Cosmetics (ShangHai) Co., Ltd. Director,Taiwan Incubator SME Development Corporation. Independent Director,Sinyi Realty Inc.	37,737,698	N.A
2	Director	Lee I-Lin	female	MBA, Carnegie Mellon University B.Acc., National Taiwan University	Product Manager(Sales and Marketing), Janssen Pharmaceutical Factory of Johnson & Johnson. Auditor/Risk Assessment Consultant, Deloitte Taiwan. Fierce Women in Biopharma, Taiwan 2025. Ten Outstanding Young Women of the Republic of China (2026)	Vice Chairman/General Manager, PhytoHealth Corp. Executive Director,Maywufa Company Ltd. Vice Chairman,AmCad BioMed Corp. Vice Chairman,Broadsound Corporation Supervisor,Maywufa Cosmetics (ShangHai) Co., Ltd. Supervisor,Taiwan Bio Industry Organization	196,845	N.A
3	Director	Maywufa Company Ltd. Representative:Lee Chen-Chai	male	Honorary Ph.D. ,National Taipei University of Technology. EMBA, National Chengchi University. B.Pharma.,School Of	Founder/Chairman,PhytoHealth Corp. Founder/Chairman,AmCad BioMed Corp. Chairman,Broadsound Corporation National Policy Consultants, Presidential Palace.	Founder/ Director,PhytoHealth Corp. Chairman,Maywufa Company Ltd. Founder/ Director,AmCad BioMed Corp. Chairman,Taiwan Incubator SME Development Corporation	37,737,698	N.A

NO.	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. of shares currently held (Shares)	Remarks
				Pharmacy, Kaohsiung Medical University.	Director, Central Bank of the Republic of China (Taiwan). Representatives of the National Assembly. Director, Straits Exchange Foundation Chairman, Taiwan Federation of Industry. Chairman, Taiwan Province Industry Association.			
4	Director	Maywufa Company Ltd. Representative: Lai Yu-Ju	male	MBA, UCLA. BBA, National Taiwan University.	VP, Citibank, Taiwan. The Ernst & Young Entrepreneur of the Year Awards in 2012.	Director, PhytoHealth Corp. Director /General Manager, Maywufa Company Ltd. Chairman, Maywufa Cosmetics (ShangHai) Co., Ltd. Director, Taiwan Incubator SME Development Corporation.	37,737,698	N.A
5	Director	Li Ling Investment Company Ltd. Representative: Lee Yu-Chia	male	EMBA, National Taiwan University of Science and Technology.	Director, Commerce Development Research Institute. Vice Chairman, Small And Medium Enterprise Foundation, Taiwan. Committee Member, Ministry Of Health And Welfare.	Director, Maywufa Company Ltd. Director, Taiwan Incubator SME Development Corporation. Director, Mender International Co., Ltd. Chairman, Yi Xin International Company Ltd. Managing Director, National Association Of Small & Medium Enterprises ,R.O.C. Director, Small And Medium Enterprise Credit Guarantee Fund Of Taiwan. Independent Director, Pershing Technology Services Corporation.	30,000	N.A
6	Director	Li Ling Investment Company Ltd. Representative: Wang Pai-Sen	male	EMBA, Tulane University B.Pharm., School of Pharmacy, Kaohsiung Medical University.	Chairman/President, Fresenius Medical Care Taiwan Co., Ltd. Chairman/General Manager, Astrazeneca Taiwan Limited. General Manager of the Western Medicine and Trade Division, of Taiwan Bu Neimen (ICI)	Director, PhytoHealth Corp. Chairman, Enrich Visions International Co., Ltd. Independent Director, TFBS Bioscience Inc. Director, YES Health Co., Ltd.	30,000	N.A

NO.	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. of shares currently held (Shares)	Remarks
					Chemical Industry Co.,Ltd. Executive Director and Convener of the Public Affairs Committee, International Research-Based Pharmaceutical Manufacturers Association, IRPMA.			
7	Director	Hua Wei Ltd. Representative: Tsai Ching-Chung	male	B. Pharma, School of Pharmacy, Kaohsiung Medical University	Director/Vice General Manager, China Chemical & Pharmaceutical Co., Ltd. Director, Sino-Japan Chemical Co.,Ltd. Consultant, China Chemical & Pharmaceutical Co., Ltd. Consultant, PharmaCore Biotech Co., Ltd.	Director/Senior Consultant, PhytoHealth Corp. Consultant, Standard Chemical & Pharmaceutical Co. Ltd.	46,000	N.A
8	Director	Hua Wei Ltd. Representative: Wang Ming-Fu	male	Ph. D. of Medical Sciences, The University of Tokushima, Japan Master of Medical in Nutrition, The University of Tokushima, Japan. B.Pharm. / Pharmacist, School of Pharmacy, China Medical University	Research Fellow of Life Science and Technology institute, Japan. Instructor of Tokushima Bunri University, Japan The founding Chairman of Anti-aging and Health Society of Taiwan. Director of the Department of Food and Nutrition of Providence University. Dean of Student Affairs / Research of Providence University. Director of Innovation Incubation Center of Providence University. Dean of the College of Health Sciences, Yuanpei University of Medical Technology. President / Director, Yuanpei University of Medical Technology.	Director, PhytoHealth Corp. Chair Professor/School Affairs Consultant, Department of Food and Nutrition, Providence University. Director of International Aging Industry Research and Development Center, Providence University. Visiting Professor of International Nutrition Research, Jyumonjigakuenjyoshidaigaku. Director of Health Food Society of Taiwan. Examiner, Review Committee of Healthy Food, Ministry of Health and Welfare. Convener/Advisory Committee Member, Review Committee of Healthy Food, Ministry of Health and Welfare. Independent Director, Bio-Jourdeness International Group Co., Ltd. Director, Foundation for East-West	46,000	N.A

NO.	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. of shares currently held (Shares)	Remarks
						Medicine.		
9	Director	Huang Tse-Hung	male	Doctor of Medical Science, Institute of Clinical Medicine Chang Gung University. Master's of Program in Traditional Chinese Medicine, School of Traditional Chinese Medicine, Chang Gung University. MBBS, School of Medicine, China Medical University.	Director, Chinese Medicine Department of Keelung Chang Gung Memorial Hospital. Chief Resident, Chinese Medicine Department of Taoyuan Chang Gung Memorial Hospital. Resident, Chinese Medicine Department of LinKou Chang Gung Memorial Hospital. Doctor, Capital Medical University.	Director, PhytoHealth Corp. Convener, Traditional Chinese Medicine Development of Chang Gung Medical System. Director, Chinese Medicine Department of LinKou Chang Gung Memorial Hospital. Assistant Professor, Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology. Professor, College of Chinese Medicine of Chang Gung University. Assistant Professor, MingChi University of Technology Department of Chemical Engineering.	0	N.A
10	Independent Director	Lin Shoei-Loong	male	MMS, University of Hawaii. MBBS, National Taiwan University College of Medicine.	Surgical Research Fellow, Johns Hopkins University School of Medicine. Assistant Professor of Surgery, National Taiwan University College of Medicine. Superintendent of the hospital, Choninn Medical System. Clinical Professor of Surgery, Taipei Medical University. Clinical Professor of Surgery, National Yang-Ming University. CEO, Hospital Administration. Commission, Department of Health. Chairman, Taiwan Public Hospital Association. Chairman, Taiwan Drug Relief Foundation. Director of the hospital, Ministry of Health	Independent Director, PhytoHealth Corp. Chairman, Nan-Hsing Medical Foundation. Evaluation Committee, Institute for Biotechnology and Medicine Industry. Superintendent, Taipei Jen-Chi Relief Institution.	0	N.A

NO.	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. of shares currently held (Shares)	Remarks
					and Welfare Puzi Hospital. Director of the hospital, Ministry of Health and Welfare Tainan Hospital. Director of the hospital, Ministry of Health and Welfare Chia Yi Hospital. Director of the hospital, Ministry of Health and Welfare Taipei Hospital. Director, Joint Commission of Taiwan. Committee Member, Joint Commission of Taiwan.			
11	Independent Director	Lai Sun-Quae	male	Ph.D.of Business Administration, National Taiwan University. MBA,Indiana University of Pennsylvania. BBA, Soochow University.	Chairman,Topco Scinetific Co., Ltd. Chairman,CSBC Corporation, Taiwan. Director,Small and Medium Enterprise Administration, Ministry of Economic Affairs Deputy Director General,Department of Commerce, MOEA	Independent Director, PhytoHealth Corp. Independent Director, Yi Jinn Industrial Co., Ltd. Independent Director, Metaage Corporation. Vice Chairman / CSO, TOPCO Group. Chairman, ECO Technical Services Co., Ltd. Chairman, Yun Yue Technology Co., Ltd. Chairman, Unitech New Energy Engineering Co., Ltd. Director, Jia Yi Energy Co., Ltd. Director, Anyong Freshmart, Inc. Chairman, Yao Yue Green Energy Co., Ltd. Director, Reset Resource Technologies Co., Ltd. Independent Director, Kwang Ming Silk Mill Co., Ltd.	0	YES (Remarks1)
12	Independent Director	Wu Yang-Chang	male	Pharmacy Postdoctoral Fellow, University of North Carolina College / Meijo University College	Chair Professor / Director, Kaohsiung Medical University Research Center for Natural Products and Drug Development. Chair Professor / Vice-President, China	Independent Director, PhytoHealth Corp. Dean's Office Consultant, China Medical University Hospital.	0	NO

NO.	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. of shares currently held (Shares)	Remarks
				Doctor / Master, Kaohsiung Medical University B.Pharm., School of Pharmacy, Kaohsiung Medical University	Medical University School of Pharmacy / Chinese Medicine. Committee Member of the East Asian Herbal Medicine Expert Committee of United States Pharmacopeia. Director of Research and Development Office, Kaohsiung Medical University. Convener of the Pharmaceutical and Traditional Chinese Medicine Sciences Panel, Biological Division, National Science and Technology Council. Member of the Traditional Chinese Medicine Committee of the Department of Health, Executive Yuan. Director / Professor, Kaohsiung Medical University Research Center for Natural Products and Drug Development. Executive director / Chairman of National Standards Technical Committee, Niu-Chang-Chih, Industry Association, Taiwan. Chair Professor, Graduate Institute of Integrated Medicine, China Medical University.	Member of National Standards Technology Committee, Bureau of Standards, Metrology and Inspection, Ministry of Economic Affairs, Taiwan. Supervisor, International Symposium of Biocatalysis and Agricultural Biotechnology (ISBAB). Supervisor, Taiwan Association of Traditional and Complementary Medicine Chair Professor, Pharmacetical Sciences Program, China Medical University.		
13	Independent Director	Cheng Chien-Hsin	male	Ph.D.in Chemical Engineering, University Of Michigan. M.S. in Chemical Oklahoma State University. B.S. in Chemical Engineering Tunghai University, Taiwan.	Director and General Manager, San Fu Biotech Co., Ltd. Director, PhytoHealth Corp. General Manager, PhytoHealth Corp. Vice President/Acting President, Development Center for Biotechnology Director, Biotechnology and Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs. Technology Expert, Department of Industrial Technology, Ministry of	Director and General Manager, BioPhoenix Co., Ltd.	0	NO

NO.	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. of shares currently held (Shares)	Remarks
					Economic Affairs(supervising Biotechnology,pharmaceuticals, nanometer, and materials Chemistry)			

Remarks : Reasons for serving as independent director for three consecutive terms.

Remarks1 : Mr.Lai Sun-Quae, an independent director candidate for the current term, has served as an independent director of the Company for more than three consecutive terms. The reason for his continued nomination is that he possesses professional expertise in finance, accounting, and business administration required by the Company, and can therefore contribute his expertise.

through video conference still reaches the statutory quota for the shareholders' meeting, the shareholders' meeting shall continue.

There is no need to postpone or continue the meeting in accordance with the provisions of Paragraph 1.

In the event that the meeting should continue as mentioned in the preceding paragraph, the shareholders who participate in the shareholders meeting via video conference shall count the number of shares present in the total number of shares of the shareholders present, but shall be deemed as abstaining from voting on all the resolutions of the shareholders meeting.

Article 18 : When the company holds a video-conference shareholders meeting, it shall provide appropriate alternative measures for shareholders who have difficulties in attending via video-conferencing.

Article 19 : The chairperson may direct the security personnel (or security guards) to assist in maintaining order in the meeting venue. When the security personnel (or guards) are present to assist in maintaining order, they should wear armbands marked with the words "Security Personnel."

Article 20 : These rules will come into force after being approved by the shareholders' meeting, and the same will apply when they are amended. These rules of procedure were established on March 1, 2000. The first revision was on May 20, 2002. The second revision was on May 24, 2023.

The third revision was on November 26, 1999. The fourth revision was on March 1, 2000. The fifth revision was on September 22, 2000. The sixth revision was on June 14, 2001. The seventh revision was on May 20, 2002. The eighth revision was on June 15, 2004. The ninth revision was on November 26, 2004. The tenth revision was on November 26, 2004. The eleventh revision was made on May 25, 2005. The twelfth revision was made on June 9, 2006. The thirteenth revision was made on June 15, 2007. The fourteenth revision was made on December 28, 2007. The fifteenth revision was on June 19, 2008. The sixteenth revision was on June 16, 2009. The seventeenth revision was made on June 15, 2010. The eighteenth revision was on June 10, 2011. The nineteenth revision was on June 6, 2012. The twentieth revision was made on June 12, 2014. The twenty-first revision was made on May 27, 2016. The twenty-second revision was on June 13, 2017. The twenty-third revision was made on May 28, 2019. The twenty-fourth revision was made on May 24, 2023. The twenty-fifth revision was made on June 4, 2025.

PhytoHealth Corporation

Chairman: Lee Yi-Li

